title: Anti-proliferative effects of qianliening capsules on prostatic hyperplasia in vitro and in vivo.
abstract: Previous studies by our group showed that Qianliening capsules (QC), a clinically proven effective traditional Chinese formulation that has long been used in the treatment of benign prostatic hyperplasia (BPH), is capable of inhibiting BPH in vivo and in vitro via the promotion of apoptosis, suppression of the EGFR/STAT3 signaling pathway and regulating the expression of sex hormones as well as their receptors. However, the mechanism of its anti-BPH activity has remained to be fully elucidated. The present study aimed to investigate the mechanism underlying the anti-proliferative effect of QC in vivo and in vitro. Castrated male Sprage-Dawley (SD) rats where subcutaneously injected with testosterone propionate and the WPMY-1 cell line was stimulated with basic fibroblast growth factor in order to generate BPH in vivo and in vitro separately, both of which were then subjected to QC treatment. Finasteride was used as a positive control drug for the in vivo study. In the present study, it was found that treatment with QC or finasteride significantly reduced the prostatic index (PI=prostate wet weight/body weight x 100) in a rat model of BPH (P<0.05). In addition, reverse transcription quantitative polymerase chain reaction (RT-PCR) and western blot analyses showed that QC or finasteride treatment significantly inhibited model construction-induced upregulation of expression of proliferating cell nuclear antigen, cyclin D1 and cyclin-dependent kinase 4 in prostatic tissues of rats with BPH (P<0.05). The in vitro study further proved that QC exhibited anti-proliferative properties via G1/S cell cycle arrest in the WPMY-1 cell line, as evidenced by colony formation, flow cytometric cell cycle, immunoblot and RT-PCR analyses. In conclusion, the present study demonstrated that inhibition of cell proliferation via G1/S cell cycle arrest may be one of the underlying mechanisms of the effect of QC on BPH.
authors.affiliation: Department of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, P.R. China.
authors.forename: Xiaoyong
authors.initials: X
authors.lastname: Zhong
authors.affiliation: Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, P.R. China.
authors.forename: Jiumao
authors.initials: J
authors.lastname: Lin
authors.affiliation: Department of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, P.R. China.
authors.forename: Jianheng
authors.initials: J
authors.lastname: Zhou
authors.affiliation: Department of Pharmacology, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, P.R. China.
authors.forename: Wei
authors.initials: W
authors.lastname: Xu
authors.affiliation: Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, P.R. China.
authors.forename: Zhenfeng
authors.initials: Z
authors.lastname: Hong
mesh_terms: D000818:Animals; D002214:Capsules / Q000737:chemistry; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D019938:Cyclin D1 / Q000235:genetics / Q000378:metabolism; D051358:Cyclin-Dependent Kinase 4 / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000494:pharmacology*; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D059585:G1 Phase Cell Cycle Checkpoints / Q000187:drug effects; D008297:Male; D018809:Proliferating Cell Nuclear Antigen / Q000235:genetics / Q000378:metabolism; D011467:Prostate / Q000378:metabolism / Q000473:pathology*; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D059807:S Phase Cell Cycle Checkpoints / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D002214:Capsules; D004365:Drugs, Chinese Herbal; D018809:Proliferating Cell Nuclear Antigen; C579120:qianliening; D016222:Fibroblast Growth Factor 2; D019938:Cyclin D1; D051358:Cyclin-Dependent Kinase 4
references.citation: Clin Invest Med. 2008;31(1):E8-E15
references.pmid: 18312749
references.citation: Nat Med. 1998 Oct;4(10):1103-6
references.pmid: 9771732
references.citation: J Am Osteopath Assoc. 2000 Feb;100(2):89-96
references.pmid: 10732392
references.citation: J Ethnopharmacol. 2011 Jan 27;133(2):634-41
references.pmid: 21073943
references.citation: AAPS J. 2006;8(1):E204-21
references.pmid: 16584130
references.citation: Clin Ther. 2007 Mar;29(3):387-98
references.pmid: 17577460
references.citation: Urology. 2003 Sep;62(3 Suppl 1):6-14
references.pmid: 12957195
references.citation: BMC Complement Altern Med. 2012;12:48
references.pmid: 22520510
references.citation: Prostate. 1990;16(1):71-80
references.pmid: 1689483
references.citation: Mayo Clin Proc. 1998 Jun;73(6):590-6
references.pmid: 9621869
references.citation: Am J Pathol. 2001 Jul;159(1):139-47
references.pmid: 11438462
references.citation: Evid Based Complement Alternat Med. 2013;2013:408734
references.pmid: 23690843
references.citation: Chin J Integr Med. 2012 Nov;18(11):824-30
references.pmid: 23086486
references.citation: Urology. 2003 Sep;62(3 Suppl 1):24-33
references.pmid: 12957197
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4166-70
references.pmid: 19237565
references.citation: Cell. 2000 Jan 7;100(1):71-8
references.pmid: 10647932
references.citation: Hum Pathol. 1996 Jul;27(7):668-75
references.pmid: 8698310
references.citation: Exp Ther Med. 2013 May;5(5):1293-1300
references.pmid: 23737867
references.citation: Curr Urol Rep. 2008 Jul;9(4):272-8
references.pmid: 18765125
references.citation: Int J Impot Res. 2008 Dec;20 Suppl 3:S11-8
references.pmid: 19002119
references.citation: Zhonghua Nan Ke Xue. 2002;8(3):190-3
references.pmid: 12478841
references.citation: J Urol. 1997 Jul;158(1):217-21
references.pmid: 9186363
references.citation: Cell Growth Differ. 1996 Nov;7(11):1571-8
references.pmid: 8930407
references.citation: Cytopathology. 2004 Feb;15(1):25-31
references.pmid: 14748788
references.citation: Urology. 2000 Nov 1;56(5 Suppl 1):3-6
references.pmid: 11074195
references.citation: Oncogene. 1995 Jul 20;11(2):211-9
references.pmid: 7624138
references.citation: Zhonghua Nan Ke Xue. 2009 May;15(5):452-4
references.pmid: 19514561
references.citation: Urologe A. 1989 Nov;28(6):321-8
references.pmid: 2481358
references.citation: Drugs Today (Barc). 2002 Dec;38(12):867-76
references.pmid: 12582474
references.citation: Cochrane Database Syst Rev. 2000;(2):CD001423
references.pmid: 10796790
references.citation: Nature. 1995 Mar 9;374(6518):131-4
references.pmid: 7877684
references.citation: Mol Med Rep. 2013 Mar;7(3):848-54
references.pmid: 23314795